Genentech prevails in Baxalta haemophilia treatment suit
17-01-2022
Novartis to sell Roche shares back for $20.7 billion
05-11-2021
29-06-2021
photogearch / iStockphoto.com
Roche subsidiary Genentech received $209.5 million in unnecessary payments from Novartis Pharma for a patent licensing deal and is now refusing to return the payment, the Swiss pharma giant has alleged in a redacted complaint.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
Novartis, Genentech, US District Court for the Northern District of California, Chiron Corporation